All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-01-30T13:23:15.000Z

iStopMM study: A revised definition for LC MGUS in patients with preserved kidney function

Jan 30, 2024
Share:
Learning objective: After reading this article, learners will be able to recall the new definitions for light-chain monoclonal gammopathy of undetermined significance suggested by the iStopMM study.

Bookmark this article

Light-chain monoclonal gammopathy of undetermined significance (LC MGUS) is a form of MGUS characterized by an abnormal free light-chain (FLC) ratio with elevated serum free kappa and lambda light chains. The current definition for LC MGUS is based on a small cohort (n = 282) of healthy individuals. It has since been developed for individuals with impaired kidney function, but not those with preserved kidney function.1

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Einarsson Long presented results from the iStopMM study (NCT03327597), highlighting a novel definition for LC MGUS based on serum FLC measurements in individuals with normal kidney function (estimated glomerular filtration rate ≥60 mL/min/1.73 m2).

Design1

The overall trial design of the iStopMM study has been previously outlined by the Multiple Myeloma Hub.

The standard definition for LC MGUS in patients with preserved kidney function is:

  • serum kappa; 3.3–19.4 mg/L;
  • serum lambda; 5.7–26.3 mg/L; and
  • FLC ratio; 0.26–1.65.

This analysis aimed to redefine the reference intervals for individuals with preserved kidney function, to limit overdiagnosis of LC MGUS. Overall,

  • 75,422 individuals from the total iStopMM population aged ≥40 were screened for LC MGUS using serum protein electrophoresis, immunofixation, and serum FLC assay;
  • 41,882 individuals who had normal kidney function were screened for FLC reference intervals; and
  • two-thirds of MGUS cases were randomized for follow-up.

Results1

  • A correlation was observed between increasing age and serum kappa FLC (p = 0.27; p < 0.001), lambda FLC (p = 0.14; p < 0.001), and FLC ratio (p = 0.16; p < 0.001).
  • A revised set of reference values was recommended for individuals with normal kidney function (Table 1).

Table 1. Revised intervals by age*

Reference intervals, mg/L (unless otherwise specified)

Age <70 years
(n = 33,181)

Age >70 years
(n = 8,701)

Kappa

6.3–39.0

7.0–55.8

Lambda

5.9–36.7

6.4–48.0

FLC, ratio

0.44–2.16

0.46–2.59

FLC, free light chain.
*Adapted from Einarsson Long.1

  • Prevalence of LC MGUS based on the standard definition was 1.54% (95% confidence interval [CI], 1.46–1.63) compared with 0.26% (95% CI, 0.23–0.30) using the iStopMM criteria;
  • this equates to an 83% decrease in LC MGUS diagnosis with the novel criteria; and
  • individuals who met the standard criteria for LC MGUS but not the revised definition showed no progression within a 3.5-year follow-up period.

An outline of the revised definition for LC MGUS is shown in Figure 1.

Figure 1. Revised definition of LC MGUS* 

eGFR, estimated glomerular filtration rate; FLC, free-light chain; LC MGUS, light-chain monoclonal gammopathy of undetermined significance.
*Adapted from Einarsson Long.1

Conclusion

Previously, the standard reference intervals for LC MGUS diagnosis were based on a small cohort of patients and lead to inaccurate thresholds, especially for younger individuals. This revised definition of LC MGUS, based on the iStopMM study, demonstrated significantly lower rates of false positive diagnoses, which could reduce unnecessary health anxiety in patients and aid in the provision of healthcare resources.

  1. Einarsson Long T. Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the iStopMM study. Oral abstract #535. 65th American Society of Hematology Annual Meeting and Exposition; Dec 10, 2023; San Diego, US.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox